CD19 and non-Hodgkin lymphoma: We observed a relapse-free survival (RFS) of 81.2% in the NHL cohort, which should be compared to larger series of patients treated with anti-CD19 CAR T cells that reported one-year RFS of 65% and 79%35,36.